Our international life sciences team has built strong relationships with leading financial institutions and investors in the sector.
Access to capital from VCs, private equity and the capital markets is of crucial importance to the development of successful biotechs. However, in addition to the economic rationale for investment and M&A, our experience shows that when investing in biotechs many investors and strategic partners also rely on the quality of management and business relationships when considering which companies to invest in.
Our in-depth knowledge of the life sciences sector, together with the strength of our relationships with a wide variety of industry stakeholders is a rare quality in a law firm and one which banks and investors tell us adds real value to their transactions.
Our experience includes:
Circassia Pharmaceuticals on the syndicate of underwriting banks on Circassia’s £581m IPO on the London Main Market in March 2014, London’s largest biotech flotation for decades.
Cryo-Save on the secondary listing of the largest adult stem cell storage bank in Europe and its shares on Euronext Amsterdam by NYSE Euronext (alongside the company’s listing on AIM).
LEO Pharma on its US$1bn acquisition of Warner Chilcott’s dermatology franchise.
Rothschild and J.P.Morgan Cazenove as joint sponsors, and Rothschild as financial adviser, to BTG plc in connection with its acquisition of Biocompatibles International plc.
Sinochem on an agreement with Netherlands based DSM Anti-Infectives, to form a 50/50 global anti-infectives joint venture.